March 2017

New Product - Folotyn

Folotyn (pralatrexate) is an antineoplastic folate analogue that is a substrate for reduced folate transporters, including reduced folate carrier 1 (RFC-1) and the enzyme folylpolyglutamyl synthetase (FPGS), resulting in internalisation and accumulation within tumour cells. Pralatrexate exerts antifolate activity via the inhibition of dihydrofolate reductase (DHFR), resulting in a disruption of DNA synthesis and subsequent tumour cell death. Folotyn is indicated for the treatment of adults with peripheral T cell lymphoma (nodal, extranodal, and leukaemic/ disseminated) who have progressed after at least one prior therapy. Folotyn is contraindicated during breastfeeding. Folotyn is available as a 20 mg/1 mL and 40 mg/2 mL solution for infusion in pack sizes of 1 vial.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629